Introduction
Ptk2 Gene Focal Adhesion Kinase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
flowchart TD
PTK2["PTK2"] -->|"activates"| SRC["SRC"]
PTK2["PTK2"] -->|"interacts with"| Aging["Aging"]
PTK2["PTK2"] -->|"regulates"| Ms["Ms"]
PTK2["PTK2"] -->|"interacts with"| Cancer["Cancer"]
PTK2["PTK2"] -->|"interacts with"| Neurodegeneration["Neurodegeneration"]
PTK2["PTK2"] -->|"associated with"| Carcinoma["Carcinoma"]
PTK2["PTK2"] -->|"associated with"| Cancer["Cancer"]
PTK2["PTK2"] -->|"associated with"| Tumor["Tumor"]
PTK2["PTK2"] -->|"associated with"| SRC["SRC"]
PTK2["PTK2"] -->|"interacts with"| SIRT1["SIRT1"]
PTK2["PTK2"] -->|"interacts with"| SIRT7["SIRT7"]
PTK2["PTK2"] -->|"regulates"| Epigenetic["Epigenetic"]
PTK2["PTK2"] -->|"interacts with"| Autophagy["Autophagy"]
PTK2["PTK2"] -->|"interacts with"| Mtor["Mtor"]
style PTK2 fill:#4fc3f7,stroke:#333,color:#000Protein Tyrosine Kinase 2 (PTK2), also known as Focal Adhesion Kinase (FAK), is a critical non-receptor tyrosine kinase that plays essential roles in cell adhesion, migration, proliferation, and survival. In the nervous system, PTK2 is involved in neuronal development, synaptic plasticity, and neural repair mechanisms. Dysregulation of PTK2 signaling has been implicated in various neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and stroke. 1FAK in neuronal development and synaptic plasticity. Neuroscientist. 2015;21(3):237-251Open reference
PTK2 functions as a central signaling hub at focal adhesions, where it integrates signals from integrins, growth factor receptors, and mechanical stimuli to coordinate cellular responses essential for neural circuit formation and maintenance. 2FAK and neurodegeneration. J Mol Neurosci. 2018;64(3):351-359Open reference
Molecular Function
Structure
PTK2 encodes a 125 kDa protein consisting of several functional domains:
-
N-terminal FERM domain (4.1, ezrin, radixin, moesin): Binds to PIP2, growth factor receptors, and cytoskeletal proteins
-
Central kinase domain: Catalytic domain with tyrosine kinase activity
-
C-terminal focal adhesion targeting (FAT) domain: Mediates localization to focal adhesions
Activation Mechanism
PTK2 activation occurs through a multistep process:
-
Integrin engagement: Cell adhesion to extracellular matrix triggers integrin clustering
-
Autophosphorylation: Y397 autophosphorylation creates an SH2 binding site
-
Src recruitment: Src family kinases bind to phosphorylated Y397
-
Full activation: Src phosphorylates additional tyrosine residues (Y576/Y577) in the kinase domain
Signaling Pathways
Activated PTK2 engages multiple downstream signaling cascades:
-
MAPK/ERK pathway: Regulates cell proliferation and differentiation
-
PI3K/Akt pathway: Promotes cell survival and metabolic regulation
-
Rho GTPases: Controls cytoskeletal dynamics and cell migration
-
p130Cas/FAK: Mechanical signaling and focal adhesion turnover
Expression Pattern
Brain Region Distribution
PTK2 shows widespread expression throughout the brain:
-
Cerebral cortex: High expression in pyramidal neurons
-
Hippocampus: Prominent in CA1-CA3 regions and dentate gyrus
-
Basal ganglia: Moderate expression in striatal neurons
-
Cerebellum: Purkinje cells and granule cells
-
Substantia nigra: Dopaminergic neurons
Cell-Type Specificity
-
Neurons: High expression, especially in dendritic spines
-
Astrocytes: Moderate expression, involved in astrocytic migration
-
Microglia: Low baseline, upregulated in neuroinflammation
-
Endothelial cells: High expression in brain vasculature
Role in Neurodegeneration
Alzheimer’s Disease
PTK2/FAK plays complex roles in AD pathogenesis:
-
Amyloid-beta effects: Aβ exposure leads to altered FAK signaling in neurons
-
Tau pathology: FAK interacts with tau phosphorylation pathways
-
Synaptic dysfunction: FAK regulates synaptic plasticity through AMPA and NMDA receptor modulation
-
Neuroinflammation: Glial FAK activation contributes to inflammatory responses
Parkinson’s Disease
In PD models:
-
Dopaminergic neuron survival: FAK signaling modulates viability of substantia nigra neurons
-
α-Synuclein pathology: FAK activation observed in Lewy body diseases
-
Mitochondrial dysfunction: FAK intersects with mitochondrial quality control pathways
Stroke and Ischemia
PTK2 is critically involved in ischemic injury and recovery:
-
Acute phase: Rapid FAK activation in response to oxygen-glucose deprivation
-
Blood-brain barrier: FAK regulates endothelial junction integrity
-
Neuroprotection: FAK inhibition reduces infarct size in experimental models
-
Repair mechanisms: FAK promotes angiogenesis and neural regeneration
Therapeutic Implications
PTK2 represents a potential therapeutic target:
-
FAK inhibitors in clinical trials for cancer may have neurological applications
-
Blood-brain barrier penetration remains a challenge for CNS drug development
-
Selective modulation of specific FAK functions needed to avoid adverse effects
Key Publications
-
Zhou J, et al. FAK and neurodegeneration. J Mol Neurosci. 2018;64(3):351-359
-
Ricomando MP, et al. FAK in Alzheimer’s disease brain. J Alzheimers Dis. 2017;58(2):373-382
-
Yang J, et al. FAK in Parkinson’s disease. Mol Neurobiol. 2019;56(8):5682-5694
-
Liu J, et al. FAK and stroke: From pathophysiology to therapy. Neurochem Res. 2020;45(8):1738-1749
-
Ozden C, et al. FAK in neuroinflammation. Glia. 2021;69(8):1942-1958
-
Lee JY, et al. FAK inhibition as neuroprotective strategy. Neuropharmacology. 2022;203:108870
See Also
External Links
Background
The study of Ptk2 Gene Focal Adhesion Kinase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
- FAK in neuronal development and synaptic plasticity. Neuroscientist. 2015;21(3):237-251
- FAK and neurodegeneration. J Mol Neurosci. 2018;64(3):351-359
- FAK in Alzheimer's disease brain. J Alzheimers Dis. 2017;58(2):373-382
- FAK in Parkinson's disease. Mol Neurobiol. 2019;56(8):5682-5694
- FAK and stroke: From pathophysiology to therapy. Neurochem Res. 2020;45(8):1738-1749
- FAK in neuroinflammation. Glia. 2021;69(8):1942-1958
- FAK inhibition as neuroprotective strategy. Neuropharmacology. 2022;203:108870
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.